Our EphA4 (Tyr-602)) phosphospecific primary antibody from PhosphoSolutions is rabbit polyclonal. It detects chicken, human, mouse, and rat EphA4 (Tyr-602)) and is antigen affinity purified. It is great for use in WB, IHC.
Paraformaldehyde-fixed zebrafish embryos were probed with anti-EphA4 (Tyr-602) (EP2731) then detected using Alexa Fluor 647 goat anti-rabbit. Arrows show labeling of somite boundaries and the notochord. (Image provided by Dr. Scott Holley at the Department of Molecular, Cellular and Developmental Biology, Yale University.)
The Eph family of Receptor tyrosine kinases and their Ephrin ligands are important for cell positioning and morphogenesis during development. Eph receptors are classified into 10 EphA and 6 EphB receptors, which preferentially bind to the type A and type B ephrins, respectively. The EphA4 receptor can inhibit axon outgrowth and has roles in regulating axon projections during neural development. EphA4 signaling pathways require its kinase activity and involve binding and activation of Rho-GTPase guanine nucleotide-exchange factors (GEFs). EphA4 activation leads autophosphorylation of Tyr-596 and Tyr-602, and the conserved sites in EphA2 are required for binding to the GEFs, Vav2 and Vav3, and ephrin-induced cell migration. The Tyr-779 site in the kinase domain is also phosphorylated in vivo and may regulate kinase activity. Activated EphA4 leads to Src kinase phosphorylation of the GEF, ephexin-1, and this activates RhoA. Thus, EphA4 signaling involves complex tyrosine phosphorylation in its cytoplasmic region along with interaction with several GEFs.
Antigen Affinity Purified
Polyclonal
IgG
IHC, WB
Rabbit
EPHA4
120
EphA4 (Tyr-602) synthetic peptide (coupled to carrier protein) corresponds to amino acids surrounding phosphorylated tyrosine 602 in human EphA4. This sequence has significant homology to the conserved site in rat and mouse EphA4, and is conserved well in most other EphA and EphB family members.
Chicken, Human, Mouse, Rat
Storage at -20°C is recommended, as aliquots may be taken without freeze/thawing due to presence of 50% glycerol. Stable for at least 1 year at -20°C.
Liquid
PBS + 1 mg/ml BSA, 0.05% NaN3 and 50% glycerol
WB: 1:1000
IHC: 1:100
Unconjugated
This antibody was cross-adsorbed to unrelated phosphotyrosine peptides before affinity purification using EphA4 (Tyr-602) peptide. The purified antibody detects a 120 kDa* band corresponding to EphA4 in Western blots of HUVEC cells treated with pervanadate and in mouse brain tissue.
Phosphorylated
Tyr-602
Western blots performed on each lot.
For research use only. Not intended for therapeutic or diagnostic use. Use of all products is subject to our terms and conditions, which can be viewed on our website.
United States
After date of receipt, stable for at least 1 year at -20°C.
Fiore, L, et al. 2019. Regulation of axonal EphA4 forward signaling is involved in the effect of EphA3 on chicken retinal ganglion cell axon growth during retinotectal mapping. Experimental eye research, 46-60.
Ortalli, AL, et al. 2012. EphA3 expressed in the chicken tectum stimulates nasal retinal ganglion cell axon growth and is required for retinotectal topographic map formation. PLoS one, e38566.
Yao, Z, et al. 2023. Age-related Decline in Hippocampal Tyrosine Phosphatase PTPRO is a Mechanistic Factor in Chemotherapy-related Cognitive Impairment. JCI Insight, e166306.
Yao, Z, et al. 2023. Age-related Decline in Hippocampal Tyrosine Phosphatase PTPRO is a Mechanistic Factor in Chemotherapy-related Cognitive Impairment. JCI Insight, e166306.
Jülich, D, et al. 2009. Control of extracellular matrix assembly along tissue boundaries via Integrin and Eph/Ephrin signaling. Development, 2913-2921.
Fiore, L, et al. 2019. Regulation of axonal EphA4 forward signaling is involved in the effect of EphA3 on chicken retinal ganglion cell axon growth during retinotectal mapping. Experimental eye research, 46-60.
Yang, L, et al. 2024. Targeted dual degradation of HER2 and EGFR obliterates oncogenic signaling, overcomes therapy resistance, and inhibits metastatic lesions in HER2-positive breast cancer models. Drug Resistance Updates, 101078.
Chiang, CW, et al. 2023. Single-chain fragment antibody disrupting the EphA4 function as a therapeutic drug for gastric cancer. Biochemical and Biophysical Research Communications, 161-170.
Zhang, S, et al. 2023. Inhibition of EphA4 reduces vasogenic edema after experimental stroke in mice by protecting the blood-brain barrier integrity. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 271678X231209607.
Yao, Z, et al. 2023. Age-related Decline in Hippocampal Tyrosine Phosphatase PTPRO is a Mechanistic Factor in Chemotherapy-related Cognitive Impairment. JCI Insight, e166306.
Yao, Z, et al. 2023. Age-related Decline in Hippocampal Tyrosine Phosphatase PTPRO is a Mechanistic Factor in Chemotherapy-related Cognitive Impairment. JCI Insight, e166306.
Fu, AKY, et al. 2014. Blockade of EphA4 signaling ameliorates hippocampal synaptic dysfunctions in mouse models of Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America, 9959-9964.
